BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 25433945)

  • 1. Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
    Zhou B; Bu G; Zhou Y; Zhao Y; Li W; Li M
    Med Oncol; 2015 Jan; 32(1):378. PubMed ID: 25433945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
    Wang Q; Qian J; Wang J; Luo C; Chen J; Hu G; Lu Y
    J Neurooncol; 2013 Mar; 112(1):73-82. PubMed ID: 23292182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of AKT2 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to the anticancer drug VM-26 in U87 glioma cells.
    Cui Y; Wang Q; Wang J; Dong Y; Luo C; Hu G; Lu Y
    Brain Res; 2012 Aug; 1469():1-9. PubMed ID: 22771706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
    Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
    Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy.
    Feng X; Zhang B; Wang J; Xu X; Lin N; Liu H
    Med Oncol; 2011 Mar; 28(1):24-30. PubMed ID: 20221717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
    Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
    Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.
    Motaln H; Koren A; Gruden K; Ramšak Ž; Schichor C; Lah TT
    Oncotarget; 2015 Dec; 6(38):40998-1017. PubMed ID: 26517510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
    Fan TY; Wang H; Xiang P; Liu YW; Li HZ; Lei BX; Yu M; Qi ST
    Int J Clin Exp Pathol; 2014; 7(10):6662-70. PubMed ID: 25400745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
    Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
    Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.
    He J; Liu C; Wang B; Li N; Zuo G; Gao D
    Int J Oncol; 2015 Oct; 47(4):1503-11. PubMed ID: 26315299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells.
    Wang J; Wang Q; Cui Y; Liu ZY; Zhao W; Wang CL; Dong Y; Hou L; Hu G; Luo C; Chen J; Lu Y
    J Neurooncol; 2012 Feb; 106(3):473-84. PubMed ID: 21912938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
    Lin J; Ji A; Qiu G; Feng H; Li J; Li S; Zou Y; Cui Y; Song C; He H; Lu Y
    Cancer Sci; 2018 Apr; 109(4):1001-1011. PubMed ID: 29427543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
    Zhou D; Wan Y; Xie D; Wang Y; Wei J; Yan Q; Lu P; Mo L; Xie J; Yang S; Qi X
    Exp Mol Med; 2015 Sep; 47(9):e182. PubMed ID: 26337869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
    Liu Q; Xue Y; Chen Q; Chen H; Zhang X; Wang L; Han C; Que S; Lou M; Lan J
    Oncol Rep; 2017 Nov; 38(5):2911-2918. PubMed ID: 29048655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.